IL17A interleukin 17A
ENSG00000112115 · protein coding · Open Targets profile
Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity (PubMed:24120361). Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:17911633, PubMed:18684971, PubMed:19825828, PubMed:21350122, PubMed:24120361, PubMed:8676080). Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity). In airway epithelium, mediates neutrophil chemotaxis via induction of CXCL1 and CXCL5 chemokines (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Effector cytokine of a subset of gamma-delta T cells that functions as part of an inflammatory circuit downstream IL1B, TLR2 and IL23A-IL12B to promote neutrophil recruitment for efficient bacterial clearance (By similarity). Effector cytokine of innate immune cells including invariant natural killer cell (iNKT) and group 3 innate lymphoid cells that mediate initial neutrophilic inflammation (By similarity). Involved in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection (PubMed:21350122). Upon acute injury, has a direct role in epithelial barrier formation by regulating OCLN localization and tight junction biogenesis (By similarity). As part of the mucosal immune response induced by commensal bacteria, enhances host's ability to resist pathogenic bacterial and fungal infections by promoting neutrophil recruitment and antimicrobial peptides release (By similarity). In synergy with IL17F, mediates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms (By similarity). Enhances immunity against West Nile virus by promoting T cell cytotoxicity (By similarity). May play a beneficial role in influenza A virus (H5N1) infection by enhancing B cell recruitment and immune response in the lung (By similarity). Contributes to influenza A virus (H1N1) clearance by driving the differentiation of B-1a B cells, providing for production of virus- specific IgM antibodies at first line of host defense (By similarity). {ECO:0000250|UniProtKB:Q62386, ECO:0000269|PubMed:17911633, ECO:0000269|PubMed:18684971, ECO:0000269|PubMed:19825828, ECO:0000269|PubMed:21350122, ECO:0000269|PubMed:24120361, ECO:0000269|PubMed:8676080}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand, High-Quality Ligand
- Antibody
- Approved Drug, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.13886000216007233 (upper bound 0.6587299704551697). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 139 registry trials, updated in the last three years, of the most advanced drugs against IL17A (ixekizumab, secukinumab, bimekizumab, M-1095, vunakizumab, izokibep, tibulizumab, remtolumab, CJM-112), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- UCB Cares001 844 599 22733 (UCB) · 28 of 32 trials Phase 2+Ph1NCT07290036 · A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adultsbrief
- Donald BetahACELYRIN Inc. · 3 of 3 trials Phase 2+
- Jo LambertUniversity Hospital, Ghent · 3 of 3 trials Phase 2+
- AIHUA DUTongji Hospital · 1 of 1 trials Phase 2+
- Alexa KimballBeth Israel Deaconess Medical Center · 1 of 1 trials Phase 2+
- Alexis Ogdie-BeattyUniversity of Pennsylvania · 1 of 1 trials Phase 2+
- Benjamin KaffenbergerDermatologist · 1 of 1 trials Phase 2+
- Elke de JongRadboud University Medical Center · 1 of 1 trials Phase 2+
- Gang Wangxjjing Hospital · 1 of 1 trials Phase 2+
- Gil YosipovitchUniversity of Miami · 1 of 1 trials Phase 2+
- Hubert MAROTTECentre Hospitalier Universitaire de Saint Etienne · 1 of 1 trials Phase 2+
- James W MurroughIcahn School of Medicine at Mount Sinai · 1 of 1 trials Phase 2+
- Jason C. SluzevichMayo Clinic · 1 of 1 trials Phase 2+
- Jeffrey R CurtisFoundation for Advancing Science Technology Education and Research · 1 of 1 trials Phase 2+
- Jiashun ZengThe Affiliated Hospital Of Guizhou Medical University · 1 of 1 trials Phase 2+
Registry trials of ixekizumab, secukinumab, bimekizumab, M-1095, vunakizumab, izokibep, tibulizumab, remtolumab, CJM-112 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 66 of 131 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 8 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
37 trials of drugs against IL17A were stopped early; 5 give no reason
Terminated, withdrawn and suspended interventional trials of ixekizumab, secukinumab, bimekizumab, M-1095, vunakizumab, izokibep, tibulizumab, remtolumab, CJM-112, perakizumab, afasevikumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 37.
- terminated · 2026-04-15 · Novartis Pharmaceuticals · Secukinumab“Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified”
- terminated · 2026-03-24 · Novartis Pharmaceuticals · Secukinumab“Project discontinued to prioritize other key programs in portfolio”
- terminated · 2025-12-18 · Novartis Pharmaceuticals · Secukinumab“Project discontinued to prioritize other key programs in portfolio”
- terminated · 2025-10-15 · ACELYRIN Inc. · Izokibep“Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.”
- terminated · 2025-05-23 · ACELYRIN Inc. · Izokibep, Placebo to izokibep“Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons.”
- terminated · 2025-05-16 · Novartis Pharmaceuticals · Secukinumab“Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301”
- terminated · 2025-05-16 · Novartis Pharmaceuticals · secukinumab“Study terminated by sponsor due to futility analysis”
- terminated · 2025-04-10 · UCB Biopharma SRL · Bimekizumab“Study recruitment temporarily halted due to difficulties executing the study under the COVID-19 pandemic”
- terminated · 2025-02-21 · ACELYRIN Inc. · Izokibep“Study primary and secondary endpoints did not achieve statistical significance.”
- terminated · 2024-05-17 · Beth Israel Deaconess Medical Center · Secukinumab“Study halted prematurely due COVID-19 pandemic and did not resume; participants are no longer being examined or receiving intervention.”
- terminated · 2024-02-29 · Novartis Pharmaceuticals · Investigational Arm - secukinumab“Low enrollment”
- terminated · 2023-07-12 · Inmagene LLC · matched by the registry's drug synonyms“The sponsor's development strategy is adjusted.”
- withdrawn · 2023-03-31 · Novartis Pharmaceuticals · Secukinumab 300 mg“low recruitment”
- terminated · 2023-03-21 · Eli Lilly and Company · matched by the registry's drug synonyms“The study was terminated due to a strategic business decision made by the Sponsor.”
- withdrawn · 2023-03-15 · Innovaderm Research Inc. · Bimekizumab“Sponsor decision.”
- withdrawn · 2023-01-09 · Novartis Pharmaceuticals · Secukinumab“Trial terminated due to strategic decision of senior management”
- terminated · 2022-11-30 · Eli Lilly and Company · Ixekizumab“At the protocol-specified interim analysis, the sponsor decided to stop the trial.”
- withdrawn · 2022-01-27 · Matthew C. Baker · tibulizumab (LY3090106)“Drug unavailable”
- terminated · 2021-09-17 · Novartis Pharmaceuticals · matched by the registry's drug synonyms“Data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period.”
- withdrawn · 2021-09-08 · Massachusetts General Hospital · Secukinumab“Difficulty recruiting participants”
- terminated · 2021-07-12 · Novartis Pharmaceuticals · matched by the registry's drug synonymsNo reason given
- withdrawn · 2021-05-28 · Wake Forest University Health Sciences · secukinumab 150 mg (2 injections per dose“Contracting never completed, closed the IRB”
- terminated · 2021-03-11 · Icahn School of Medicine at Mount Sinai · Secukinumab“low enrollment”
- withdrawn · 2020-09-29 · Novartis · matched by the registry's drug synonyms“Core study in non-infectious active uveitis was terminated”
- withdrawn · 2017-04-20 · Novartis Pharmaceuticals · "Secukinumab" "Cosentyx TM"No reason given
Paediatric incentives and obligations for IL17A's drugs
For ixekizumab, secukinumab, bimekizumab, M-1095, vunakizumab, izokibep, tibulizumab, remtolumab, CJM-112, perakizumab, afasevikumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · IL17A is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001050-PIP01-10-M05 (ixekizumab, Treatment of psoriasis): PM: decision on the application for modification of an agreed PIP, 18 Mar 2020; compliance positive 13 Oct 2023; EMEA-003325-PIP01-22 (izokibep, Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis, and juvenile idiopathic arthritis)): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 14 Jul 2023; EMEA-000380-PIP11-23 (secukinumab, Treatment of rotator cuff tendinopathy): W: decision granting a waiver in all age groups for all conditions or indications, 14 Jul 2023; EMEA-001050-PIP02-18-M02 (ixekizumab, Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)): PM: decision on the application for modification of an agreed PIP, 14 Jul 2023; compliance positive 26 Jul 2024; +11 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names ixekizumab, secukinumab, bimekizumab, m-1095, vunakizumab, izokibep, tibulizumab, remtolumab, cjm-112, perakizumab, afasevikumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Cosentyx: authorised since 14 Jan 2015; Taltz: authorised since 25 Apr 2016; Bimzelx: authorised since 20 Aug 2021Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of ixekizumab, secukinumab, bimekizumab, m-1095, vunakizumab, izokibep, tibulizumab, remtolumab, cjm-112, perakizumab, afasevikumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 20 interventional studies of ixekizumab, secukinumab, bimekizumab, m-1095, vunakizumab, izokibep, tibulizumab, remtolumab, cjm-112, perakizumab, afasevikumab include patients under 18; 8 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 11 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.